This latest approval comes a day after the company announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). Per management, the CRL...
including approvals for Skyrizi and UC, 951 in the U.S., and potentially, accelerated approval for Epkinly and third-line plus follicular lymphoma. We also anticipate
Neuroscience is another area with outstanding performance. Vraylar, Botox Therapeutic, Ubrelvy and Qulipta each ademonstrated double-digit sequential sales growth. Pending regulatory approvals for Vraylar in major depressive disorder, Qulipta in chronic migraine, and 951 for the treatment of advanced ...
expanded indications for VENCLEXTA, and several other near-term product — new product approvals including atogepant, Navitoclax and ABBV-951. Clearly, this is a very exciting time for AbbVie, and I’m pleased with the progress that we’re making towards our long-term strategy for sustainab...